68 active not recruiting. 68 Phase 1, 20 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 68 | Active not recruiting 68 |
| Phase 2 | 20 | Active not recruiting 20 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg - Opioid Use Disorder | Phase 1 | Active not recruiting | Akyso Therapeutics, LLC | 33 | 2026-07-25 | 2026-09-30 |
| Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) Semaglutide 1.0 mg - Alcohol Use Disorder, Weight Loss | Phase 1 | Active not recruiting | Yale University | 4 | 2026-03-26 | 2026-09-10 |
| Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD Psychedelic - PTSD | Phase 1 | Active not recruiting | Scottsdale Research Institute | 24 | 2026-03-20 | 2026-07-29 |
| Morning-Evening Specific Longevity Food Supplement Morning- and evening-specific compound food supplement, Control - Aging | Phase 1 | Active not recruiting | University of Primorska | 60 | 2026-03-07 | 2026-03-11 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) RO7812653, Placebo - Alzheimer's Disease | Phase 1 | Active not recruiting | Hoffmann-La Roche | 6 | 2026-01-27 | 2026-09-09 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease RG6496, Placebo - Huntington's Disease | Phase 1 | Active not recruiting | Hoffmann-La Roche | 3 | 2025-11-19 | 2026-09-02 |
| Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD) Door-through-door companion rideshare, Curb-to-curb rideshare services - Alzheimer Disease or Associated Disorder, Dementia | Phase 1 | Active not recruiting | Onward Health, Inc | 120 | 2025-08-29 | 2026-07-21 |
| Autonomous Digital CBT Intervention for Opioid Use Disorder in Individuals With Co-Occurring Internalizing Disorders NEAT-O program - Opioid Use Disorder, Anxiety | Phase 1 | Active not recruiting | University of Minnesota | 17 | 2025-08-21 | 2026-02-12 |
| A Food Effect Study of LY03020 in Healthy Subjects LY03020 - Schizophrenia, Alzheimer's Disease Psychosis | Phase 1 | Active not recruiting | Luye Pharma Group Ltd. | 16 | 2025-07-30 | 2025-12-18 |
| A Study to Assess THN391 in Subjects With Alzheimer's Disease THN391, Placebo - Alzheimer Disease, Early Onset | Phase 1 | Active not recruiting | Therini Bio, Inc. | 19 | 2025-07-17 | 2026-07-08 |
| Safety Of Nrtis for Alzheimer's Therapeutic Advancement in Singapore Study Emtricitabine (FTC), Descovy® (TAF/FTC), Placebo to Match Emtricitabine 200mg/Tenofovir Alafenamide 25 mg. - Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD) | Phase 1 | Active not recruiting | National University Hospital, Singapore | 48 | 2025-06-30 | 2026-08-10 |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase Cannabis 50 mg of CBD and 5 mg of THC - Alzheimer Disease (AD) | Phase 1 / Phase 2 | Active not recruiting | Federal University of Latin American Integration | 61 | 2025-04-07 | 2025-08-12 |
| Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders Promoting Resilience to Improve Disordered Eating - Eating Disorders, Sexual Minorities | Phase 1 | Active not recruiting | Auburn University | 30 | 2025-02-28 | 2026-07-24 |
| A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease. ER2001 intravenous injection, Placebo - Huntington Disease | Phase 1 / Phase 2 | Active not recruiting | ExoRNA Bioscience | 27 | 2025-02-11 | 2026-01-14 |
| Priming CBT With rTMS for OCD rTMS, CBT - Obsessive Compulsive Disorder (OCD) | Phase 1 | Active not recruiting | Sunnybrook Health Sciences Centre | 10 | 2025-02-05 | 2026-03-04 |
| PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) PMN310, Placebo - Alzheimer Disease, Early Onset | Phase 1 | Active not recruiting | ProMis Neurosciences, Inc | 144 | 2024-12-13 | 2026-07-13 |
| Psilocybin for Treatment-Resistant Depression in Autism Psilocybin - Treatment Resistant Depression, Autism Spectrum Disorder | Phase 1 | Active not recruiting | Centre for Addiction and Mental Health | 18 | 2024-11-01 | 2026-10-26 |
| Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression Psilocybin, Functional MRI - Bipolar Depression | Phase 1 | Active not recruiting | University Health Network, Toronto | 30 | 2024-10-09 | 2026-08-10 |
| A Study of Psilocybin for PTSD Psilocybin, Trauma-focused psychotherapy, Standard psychological support - Post Traumatic Stress Disorder | Phase 1 | Active not recruiting | Johns Hopkins University | 20 | 2024-06-07 | 2026-06-22 |
| The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) - Anxiety, Medication-refractory Focal-onset Epilepsy | Phase 1 | Active not recruiting | Ohio State University | 2 | 2024-06-04 | 2026-07-22 |
Showing 20 of 68. Sign in to see all of them.
Alzheimer Disease (16) · Marijuana Abuse (8) · Cognitive Dysfunction (6) · Depression (6) · Alcoholism (5) · Depressive Disorder, Major (5) · Huntington Disease (5) · Opioid-Related Disorders (5) · Frontotemporal Dementia (4) · Schizophrenia (4) · Anxiety Disorders (3) · Dementia (3) · Pain (3) · Stress Disorders, Post-Traumatic (3) · Agnosia (2)
Nervous System Diseases (30) · Neurocognitive Disorders (26) · Brain Diseases (25) · Central Nervous System Diseases (25) · Dementia (23) · Neurodegenerative Diseases (23) · Chemically-Induced Disorders (21) · Substance-Related Disorders (19) · Tauopathies (14) · Cognition Disorders (10) · Pathological Conditions, Signs and Symptoms (9) · Depressive Disorder (7) · Mood Disorders (7) · Signs and Symptoms (7)
Psilocybin (7) · nabiximols (3) · Dronabinol (2) · (18F)GTP1 (1) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 5,10-dihydro-5-methylphenazine (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · Capsules (1) · Cognitive Behavioral Therapy (1) · Dasatinib (1) · Deferiprone (1) · Donepezil (1) · Emtricitabine (1)
Yale University (11) · Hoffmann-La Roche (3) · New York State Psychiatric Institute (2) · UniQure Biopharma B.V. (2) · University of California, Los Angeles (2) · Akyso Therapeutics, LLC (1) · Alzamend Neuro, Inc. (1) · AskBio France, SAS, a subsidiary of AskBio Inc. (1) · Auburn University (1) · Centre for Addiction and Mental Health (1) · Denali Therapeutics Inc. (1) · Duke University (1) · Eleusis Therapeutics (1) · ExoRNA Bioscience (1) · Federal University of Latin American Integration (1)
United States (46) · Canada (12) · United Kingdom (9) · Spain (6) · Australia (4) · France (4) · China (3) · Netherlands (3) · Belgium (2) · Brazil (2) · Poland (2) · South Korea (2) · Sweden (2) · Argentina (1) · Chile (1)
Aaron Blashill, PhD (1) · Amelia Gallitano, MD,PhD (1) · Amy Berger, MD (1) · Aynur Unalp-Arida, MD, PhD (1) · Benjamin Kelmendi, MD (1) · Brian L Edlow, MD (1) · Chris Stauffer, MD (1) · Christopher Chen (1) · David H. Margolin, MD, PhD (1) · David Hasan, MD (1) · David Margolin, MD, PhD (1) · Deepak D'Souza, MD (1) · Gang Wang (1)
PMID 36463457, PMID 38489195, PMID 10870744, PMID 11165371, PMID 11786502, PMID 14621285, PMID 15647484, PMID 15800228, PMID 16508405, PMID 17123731, PMID 17237664, PMID 17433624, PMID 17635557, PMID 17853395, PMID 18294378, PMID 18362258, PMID 18378801, PMID 18419722, PMID 18619874, PMID 18774343, PMID 19198615, PMID 19409861, PMID 19789074, PMID 20031953, PMID 20086062, PMID 21029787, PMID 21148579, PMID 21249671, PMID 21358740, PMID 21412914, PMID 21765969, PMID 22336864, PMID 22494121, PMID 22898544, PMID 24068826, PMID 24661411, PMID 24867013, PMID 25221944, PMID 25418676, PMID 25872113, PMID 25957198, PMID 26029937, PMID 26302439, PMID 26987082, PMID 27407096, PMID 28074005, PMID 28106092, PMID 28119481, PMID 28409480, PMID 28767350
2023 (2), 2025 (2), U54AA027989 (2), 5UH3DA042492 (1), DP2HD101400 (1), P50AA010761 (1), R01AA029398 (1), R01AG073267 (1), R01AG073482 (1), R01AT010762 (1), R01DK132709 (1), R01MH076776 (1), R01MH087692 (1), R01MH123142 (1), R44AG085945 (1)